医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Scanditronic becomes Ascom

2014年12月16日 AM10:00
このエントリーをはてなブックマークに追加


 

KUALA LUMPUR, Malaysia & GOTHENBURG, Sweden

Ascom, a global provider of mission-critical communications systems, recently acquired Scanditronic, a distributor of Ascom’s products in Malaysia and the South East Asia region.

As of November 1st Scanditronic has changed its legal entity name to Ascom (Malaysia) Sdn. Bhd. and will be running under the Ascom Wireless Solutions division which is headquartered in Gothenburg, Sweden.

Ascom (Malaysia) will lead all of the Ascom Wireless Solutions operations in the South East Asian region, delivering mobility, nurse call and middleware solutions for the healthcare, retail, hospitality and shipping segments. The acquisition will further strengthen the support to existing customers, and enhances Ascom’s presence in South East Asia.

For more information visit www.ascom.com/ws

ABOUT ASCOM WIRELESS SOLUTIONS

Ascom Wireless Solutions (www.ascom.com/ws) is a leading provider of on-site wireless communications for key segments such as hospitals, elderly care, independent living, manufacturing industries, secure establishments, retail and hotels. More than 75,000 systems are installed at major companies all over the world. The company offers a broad range of voice and professional messaging solutions, creating value for customers by supporting and optimizing their Mission-Critical processes. The solutions are based on VoWiFi, IP-DECT, nurse call and paging technologies, smartly integrated into existing enterprise systems. The company has subsidiaries in 13 countries and 1,200 employees worldwide. Founded in 1955 and based in Göteborg, Sweden, Ascom Wireless Solutions is part of the Ascom Group, listed on the Swiss Stock Exchange.

CONTACT

Ascom Malaysia
Hans Tysk, Managing Director,
Tel: +60 342 52
47 49
Email: Hans.Tysk@ascom-ws.com

同じカテゴリーの記事 

  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
  • SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
  • Oriola Partners With HCLTech to Enhance Customer Experience Through Digital Transformation
  • Takeda将在近期召开的股东大会上公布董事会候选人名单